FLUOROPHARMA MEDICAL, INC.

Q: Mar 31 2017

FY: Dec 31 2016

Q: Jun 30 2016

Q: Sep 30 2016

Q: Jun 30 2016

Q: Mar 31 2016

FY: Dec 31 2015

Q: Sep 30 2015

Q: Jun 30 2015

Q: Mar 31 2015

FY: Dec 31 2014

Q: Sep 30 2014

Q: Sep 30 2014

Q: Jun 30 2014

Q: Mar 31 2014

FY: Dec 31 2013

Q: Sep 30 2013

Q: Jun 30 2013

Q: Jun 30 2013

Q: Mar 31 2013

5.01,5.02,9.01

1.01,2.03,3.02,9.01

1.01,3.03,5.02,9.01

2.03,5.02,9.01

1.01,3.02,9.01

Entry into a Material Definitive Agreement

2.03

1.01,5.03,5.07,9.01

1.01,9.01

7.01,9.01

Entry into a Material Definitive Agreement

Entry into a Material Definitive Agreement

Entry into a Material Definitive Agreement

1.01,2.03,3.02,9.01

1.01,9.01

5.02

5.02,9.01

1.01

5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

No description available

06b

Notice of Effectiveness

Prospectus Supplement for Primary Offering

Amended Initial Registration Statement

Amended Initial Registration Statement

Amended Initial Registration Statement

Notice of Effectiveness

Prospectus Supplement for Primary Offering

Post-effective amendment to a registration statement

Registration (IPO) statement under Securities Act of 1933

Notice of Effectiveness

Prospectus Supplement for Primary Offering

Post-effective amendment to a registration statement

06b

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Post-effective amendment to a registration statement

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Definitive Proxy Statement

Preliminary Proxy Statement

Spoor Johan M.

Spoor Johan M.

Spoor Johan M.

Spoor Johan M.

Spoor Johan M.

Spoor Johan M.

Spoor Johan M.

Spoor Johan M.

Spoor Johan M.

CHALMERS ANNA

No description available

No description available

Correspondence with the SEC

Letter from the SEC

No description available

No description available

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC

Letter from the SEC

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Letter from the SEC

Correspondence with the SEC

Correspondence with the SEC